Literature DB >> 31230371

Mepolizumab failed to affect bullous pemphigoid: A randomized, placebo-controlled, double-blind phase 2 pilot study.

Dagmar Simon1, Shida Yousefi2, Simone Cazzaniga1,3, Christina Bürgler1, Susanne Radonjic1, Carine Houriet1, Kristine Heidemeyer1, Hans-Wilhelm Klötgen1, Evelyne Kozlowski2, Luca Borradori1, Hans-Uwe Simon2,4.   

Abstract

Entities:  

Keywords:  bullous pemphigoid; eosinophil; interleukin-5; mepolizumab

Mesh：

Substances：

Year:  2019        PMID： 31230371     DOI： 10.1111/all.13950

Source DB:  PubMed          Journal:  Allergy        ISSN： 0105-4538            Impact factor:   13.146


× No keyword cloud information.
  12 in total

1.  Factors associated with the activity and severity of bullous pemphigoid: a review.

Authors:  Yangchun Liu; Yiman Wang; Xinyi Chen; Hongzhong Jin; Li Li
Journal:  Ann Med       Date:  2020-03-22       Impact factor: 4.709

Review 2.  A Review of the Immunologic Pathways Involved in Bullous Pemphigoid and Novel Therapeutic Targets.

Authors:  Mohsen Afarideh; Robert Borucki; Victoria P Werth
Journal:  J Clin Med       Date:  2022-05-18       Impact factor: 4.964

Review 3.  Current and Innovated Managements for Autoimmune Bullous Skin Disorders: An Overview.

Authors:  Kuan-Yu Chu; Hsin-Su Yu; Sebastian Yu
Journal:  J Clin Med       Date:  2022-06-19       Impact factor: 4.964

Review 4.  Controversies in Allergy: The Potential Role of Biologics as First-Line Therapy in Eosinophilic Disorders.

Authors:  Evan S Dellon; Dagmar Simon; Michael E Wechsler
Journal:  J Allergy Clin Immunol Pract       Date:  2022-02-12

Review 5.  Pemphigus and Pemphigoid: From Disease Mechanisms to Druggable Pathways.

Authors:  Christoph T Ellebrecht; Damian Maseda; Aimee S Payne
Journal:  J Invest Dermatol       Date:  2021-10-29       Impact factor: 7.590

6.  Eosinophil Knockout Humans: Uncovering the Role of Eosinophils Through Eosinophil-Directed Biological Therapies.

Authors:  Elizabeth A Jacobsen; David J Jackson; Enrico Heffler; Sameer K Mathur; Albert J Bredenoord; Ian D Pavord; Praveen Akuthota; Florence Roufosse; Marc E Rothenberg
Journal:  Annu Rev Immunol       Date:  2021-03-01       Impact factor: 28.527

Review 7.  Lessons learned from targeting eosinophils in human disease.

Authors:  Fei Li Kuang; Bruce S Bochner
Journal:  Semin Immunopathol       Date:  2021-04-23       Impact factor: 11.759

8.  Immunomodulator Galectin-9 is Increased in Blood and Skin of Patients with Bullous Pemphigoid.

Authors:  Jasper Pruessmann; Wiebke Pruessmann; Maike M Holtsche; Beke Linnemann; Christoph M Hammers; Nina van Beek; Detlef Zillikens; Enno Schmidt; Christian D Sadik
Journal:  Acta Derm Venereol       Date:  2021-03-23       Impact factor: 3.875

Review 9.  The Intersection of IgE Autoantibodies and Eosinophilia in the Pathogenesis of Bullous Pemphigoid.

Authors:  Kelly N Messingham; Tyler P Crowe; Janet A Fairley
Journal:  Front Immunol       Date:  2019-10-04       Impact factor: 7.561

Review 10.  Eosinophils in skin diseases.

Authors:  Susanne Radonjic-Hoesli; Marie-Charlotte Brüggen; Laurence Feldmeyer; Hans-Uwe Simon; Dagmar Simon
Journal:  Semin Immunopathol       Date:  2021-06-07       Impact factor: 9.623
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.